COVID-19 in Portugal: a retrospective review of paediatric cases, hospital and PICU admissions in the first pandemic year

Cecilia Elias, Rodrigo Feteira-Santos, Catarina Camarinha, Miguel de Araújo Nobre, Andreia Silva Costa, Leonor Bacelar-Nicolau, Cristina Furtado, Paulo Jorge Nogueira

ABSTRACT

Background COVID-19 is considered by WHO a pandemic with public health emergency repercussions. Children often develop a mild disease with good prognosis and the recognition of children at risk is essential to successfully manage paediatric COVID-19. Quality epidemiological surveillance data are required to characterise and assess the pandemic.

Methods Data on all reported paediatric COVID-19 cases, in Portugal, were retrospectively assessed from a fully anonymised dataset provided by the Directorate General for Health (DGS). Paediatric hospital admission results were obtained from the DGS vaccine recommendation and paediatric intensive care unit (PICU) admission results from the EPICENTRE.PT group. Reported cases and PICU admissions from March 2020 to February 2021 and hospital admissions between March and December 2020 were analysed.

Results 92 051 COVID-19 cases were studied, 50.5% males, average age of 10.1 years, corresponding to 5.4% of children in Portugal. The most common symptoms were cough and fever, whereas gastrointestinal symptoms were infrequent. The most common comorbidity was asthma. A high rate of missing surveillance data was noticed, on presentation of disease and comorbidity variables, which warrants a cautious interpretation of results. Hospital admission was required in 0.93% of cases and PICU on 3.48 per 10 000 cases. PICU admission for Multisystem Inflammatory Syndrome in Children (MIS-C) was more frequent in children with no comorbidities and males, severe COVID-19 was rarer and occurred mainly in females and infants. Case fatality rate and mortality rates were low, 1.8 per 100 000 cases and 1.2 per 1 000 000 cases, respectively.

Conclusions The overall reported case incidence was 5.4 per 100 children and adolescents and <1% of cases required hospital admission. MIS-C was more frequent in patients with no comorbidities and males. Mortality and case fatality rates were low. Geographic adapted strategies, and information systems to facilitate surveillance are required to improve surveillance data quality.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Quality health surveillance data are essential to assess the COVID-19 pandemic.
⇒ Children present a milder course of disease and a lower susceptibility to being severely affected by COVID-19.
⇒ Globally, paediatric COVID-19 case fatality and mortality rates are low.

WHAT THIS STUDY ADDS

⇒ Portuguese paediatric surveillance data and systems need improvement.
⇒ Paediatric COVID-19 incidence was 5.4% during the first pandemic year.
⇒ Portuguese children and adolescents presented an extremely low mortality and case fatality rate, 1.8 per 100 000 cases and 1.2 per 1 000 000 cases, respectively.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE AND/OR POLICY

⇒ National paediatric COVID-19 results allow for improvement at a country level.
⇒ Future research should focus on health surveillance improvement.

BACKGROUND

COVID-19, caused by SARS-CoV-2, is considered by WHO a pandemic with public health emergency repercussions.1,2 Worldwide, millions of people have been infected with COVID-19 since the end of 2019 among all age groups.3 Children are also at risk for COVID-19 but have experienced a lower incidence than other age groups.4,5 Laboratory-confirmed COVID-19 cases in the USA reveal that only 1.7% of cases were among children and adolescents under 18 years of age.6 Furthermore, several studies showed these age groups have lower susceptibility to being severely affected, often developing a
mild form of disease and with a likely good prognosis.7–9
Studies have shown that children present different symptoms, distinct comorbidities, decreased disease severity and fewer disease complications.10 The characteristics and clinical manifestations of infected children11 12 have been considered of major interest.13 The most frequent symptoms described in children have been fever, cough, and ear, nose and throat complaints. However, other manifestations such as gastrointestinal symptoms have also been identified.12 15 16 A small number of children needed hospital admission, and of these, a minority required intensive care unit (ICU) admission either due to severe COVID-19 or multisystem inflammatory disease in children (MIS-C).17 18 Several risk factors have been associated with these conditions such as extreme age, male sex, comorbidities and non-white background.19–22 As COVID-19 characteristics and clinical course among children can differ from adult patients in numerous ways, specific recommendations for the diagnosis, treatment and vaccination plans in children are being implemented worldwide, despite differences across countries.20–25 Increasing knowledge of the clinical characteristics in this demographic group may also contribute towards the development and continuous adaptation of preventive strategies that can benefit all communities. Epidemiological surveillance data are essential to attain these objectives. Epidemiological surveillance is a critical part of public health practice,24 where continuous collection, analysis and interpretation of health data help identify disease clusters, assess health trends, monitor interventions, identify high-risk groups and guide decision making and action.25 Furthermore, epidemiological data quality is essential and should be monitored to guarantee data results are meaningful.26

This study aimed to investigate the epidemiological and clinical characteristics of paediatric SARS-CoV-2 infection cases, hospital and ICU admissions, compare these with other countries and to assess the quality of epidemiological surveillance data in Portugal.

MATERIALS AND METHODS
Study design and data
Data on all cases of COVID-19 in children and adolescents under the age of 18 years, in Portugal, diagnosed between 2 March 2020 and 28 February 2021 were retrospectively assessed. The dataset was fully anonymised and was provided by the Directorate General for Health (DGS) on 11 March 2021. The data were collected by the SINAVE (National Epidemiological Surveillance System). The SINAVE is an online system aimed at the electronic notification of mandatory reporting diseases in Portugal. The SINAVE database includes demographic and clinical information collected from all reported patients. Epidemiological surveillance data in SINAVE are meant to be filled by public health doctors and nurses. However, due to the COVID-19 pandemic increased workload, other professionals from a diverse background have also been recruited to support in surveillance. According to the WHO definition, a confirmed SARS-CoV-2 case was based on a positive PCR test.27 Hospital admissions with a SARS-CoV-2 primary or secondary diagnosis, from 2 March to 31 December 2020, were obtained as results from the paediatric COVID-19 vaccination technical recommendation by DGS.28 These results include admissions to all hospitals in Portugal with a SARS-CoV-2 diagnosis. No information on whether the SARS-CoV-2 diagnosis was the primary or secondary cause of admission was available. Data on paediatric SARS-CoV-2 paediatric intensive care unit (PICU) admissions, from March 2020 to February 2021, were obtained as anonymised data results on severe COVID-1929 and MIS-C30 from the EPICENTRE. PT work group. Daily death reports published by DGS were analysed to calculate the number of deaths caused by COVID-19 and these overlapped with the recorded SINAVE case deaths. Data from the National Statistics Institute were used for mortality and population comparisons. The paediatric mid-2020 population was used by proxy as an estimate population for the period analysed.

Patient and public involvement
Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Variables
The SINAVE system includes two variables which indicate the patient’s clinical presentation (as symptomatic or asymptomatic) and comorbidities (present, absent). Information on symptoms and comorbidities associated with each case notification should also be filled in through individual variables. For a given symptom or comorbidity, health professionals selected the respective field as yes or no, according to the patient’s information. However, any information not filled, for a given symptom or comorbidity, created a missing value in the database. Considering this, a new variable was calculated to describe if a patient was symptomatic or not, using the patient’s clinical presentation variable and associated symptoms variables and similarly for the presence of comorbidities. A patient was considered symptomatic either if health professionals classified it as symptomatic through the SINAVE original variable or at least one symptom was reported. In addition, those with any symptom variable filled in but not previously recorded as symptomatic were considered symptomatic patients. Patients’ symptomatology status was missing when no symptom variables were filled, and no information regarding the presentation of symptoms in the original variable. A patient was considered having comorbidities either if the presence of comorbidities was selected through the SINAVE original variable or at least one comorbidity was reported.

Statistical analysis
Descriptive statistics were used to summarise univariate characteristics. Results were presented as absolute
and relative frequencies for qualitative variables, and as means, medians and SD for quantitative variables. Calculated percentages have excluded missing cases unless otherwise stated. All analysis were conducted using R software V.3.6.3 (R Foundation for Statistical Computing, Vienna, Austria) and IBM SPSS Statistics V.28.0.1.1 (14).

**RESULTS**

**General characteristics**

The present study included 92 051 COVID-19 cases in children and adolescents reported from 2 March 2020 to 28 February 2021, in Portugal; 46 453 (50.5%) were males and 45 583 (49.5%) females, the overall reported case incidence was 5.4 per 100 children and adolescents and corresponding to 5.3% of males and 5.5% of females. The age profile of patients was distributed between 0 and 17 years old, with the number of cases increasing with age (table 1). An average age of 10.1 (SD 5.0) and a median of 11.0 years were observed.

The geographical distribution highlights most cases occurred in three urban areas, the Lisbon district (n=22 999, 25%), followed by Porto (n=18 350, 19.9%) and Braga (n=11 091, 12%). The areas with fewer cases were predominantly rural districts (Portalegre and Beja) and autonomous regions of the Azores and Madeira (figure 1). The children and adolescents with COVID-19 had mostly Portuguese nationality (n=88 387, 95.3%).

| Age (years) | N (%) | Female n (%) | Male n (%) | Reported cases per 100 children (%) |
|------------|-------|--------------|------------|-------------------------------------|
| 0          | 1719 (1.9%) | 826 (1.8%) | 884 (1.9%) | 2.0                                 |
| 1          | 3725 (4.0%) | 1784 (3.9%) | 1940 (4.2%) | 4.3                                 |
| 2          | 3692 (4.0%) | 1800 (4.1%) | 1892 (4.1%) | 4.2                                 |
| 3          | 3332 (3.6%) | 1575 (3.5%) | 1757 (3.8%) | 3.8                                 |
| 4          | 3709 (4.0%) | 1840 (4.0%) | 1869 (4.0%) | 4.2                                 |
| 5          | 4023 (4.4%) | 1988 (4.4%) | 2035 (4.4%) | 4.6                                 |
| 6          | 4299 (4.7%) | 2128 (4.7%) | 2171 (4.7%) | 5.1                                 |
| 7          | 4592 (5.0%) | 2232 (4.9%) | 2360 (5.1%) | 5.4                                 |
| 8          | 5058 (5.5%) | 2490 (5.5%) | 2568 (5.5%) | 5.5                                 |
| 9          | 5548 (6.0%) | 2709 (6.0%) | 2839 (6.1%) | 5.7                                 |
| 10         | 5705 (6.2%) | 2872 (6.3%) | 2833 (6.1%) | 5.6                                 |
| 11         | 5726 (6.2%) | 2838 (6.2%) | 2888 (6.2%) | 5.9                                 |
| 12         | 5865 (6.4%) | 2928 (6.4%) | 2937 (6.3%) | 5.8                                 |
| 13         | 6080 (6.6%) | 2942 (6.5%) | 3137 (6.8%) | 6.1                                 |
| 14         | 6449 (7.0%) | 3235 (7.1%) | 3213 (6.9%) | 6.3                                 |
| 15         | 6919 (7.5%) | 3402 (7.5%) | 3517 (7.6%) | 6.5                                 |
| 16         | 7635 (8.3%) | 3890 (8.5%) | 3744 (8.1%) | 7.3                                 |
| 17         | 7975 (8.7%) | 4041 (8.9%) | 3932 (8.5%) | 7.4                                 |
| Subtotal 10–14 years | 29 825 (32.4%) | 14 815 (32.5%) | 15 008 (32.3%) | 5.9                                 |
| 15         | 6919 (7.5%) | 3402 (7.5%) | 3517 (7.6%) | 6.5                                 |
| 16         | 7635 (8.3%) | 3890 (8.5%) | 3744 (8.1%) | 7.3                                 |
| 17         | 7975 (8.7%) | 4041 (8.9%) | 3932 (8.5%) | 7.4                                 |
| Subtotal 15–17 years | 22 529 (24.5%) | 11 333 (24.9%) | 11 190 (24.1%) | 7.1                                 |

Fifteen (0.02%) missing values were observed for sex.

*Global percentage.
†Percentage within sex level.

Table 1  Age and sex of paediatric COVID-19-infected cases, from March 2020 to February 2021 in Portugal.

Figure 1  Map of COVID-19 paediatric cases in Portugal, by district in absolute value. (top inset box - Azores, bottom inset box - Madeira)
Only 4% were from other backgrounds, mainly from Brazil, Angola, Cape Verde, São Tome and Principe and scattered from a wide range of countries.

**COVID-19 cases timeline**

During this study, several COVID-19 epidemic waves were observed (figure 2): (1) between March and April 2020, when 738 cases were reported (0.8% of all cases); (2) between May and July 2020, when 1756 cases (1.9% of all cases) were reported; (3) from September to December 2020, when 39,897 cases (43.3% of all cases) were reported and (4) from January to March 2021, when 46,634 cases (50.7% of all cases) were reported.

**Clinical presentation**

Information on disease presentation, as symptomatic or asymptomatic, was reported in 47,470 (52%) cases while there was no information regarding the presence or absence of symptoms in 44,192 cases (48%). From cases with information on clinical presentation, 13,077 (27.5%) were asymptomatic and 34,393 (72.5%) symptomatic. Specific symptoms were reported in 21,077 (61.3%) cases and a further 13,316 (38.7%) cases were recorded as symptomatic without reporting symptoms. The asymptomatic presentation of the disease increased with age, peaking between 4 and 10 years of age and slightly decreasing subsequently.

To describe the symptomatic presentation, an analysis which included only cases where symptoms were recorded was performed (n=21,077). The most common symptoms reported were cough (n=10,205, 48.4%), fever (n=9,812, 46.6%), rhinorrhoea (n=7,739, 36.7%) and headache (n=7,143, 33.9%). Gastrointestinal symptoms, such as abdominal pain, nausea and vomiting and diarrhoea were reported in 7.1%, 7.8% and 10.2%, respectively. Analysing the distribution of the co-occurrence of clinical COVID-19 symptoms, in each paediatric patient, fever was commonly combined with cough (38.2%), rhinorrhoea (29.8%), headache (29%), odynophagia (21%) or myalgia (16.6%). Furthermore, combinations of these symptoms were the most common presentations reported. Fever, cough and rhinorrhoea were the most common presentations for children from 0 to 9 (table 2). Children aged zero presented the highest rates of fever (48%), cough (37%), rhinorrhoea (35%) and diarrhoea (24%) when compared with the other age groups. From age 10 to 17 years, headache was the most common reported symptom, followed by fever, cough and rhinorrhoea.

**Comorbidities**

Information on the presence or absence of comorbidities was reported in 19,680 (21.4%) cases and there was no information regarding the presence or absence of comorbidities in 72,371 (78.6%). A total of 1,593 patients presented with comorbidities, of which 1,000 were specified. The three most frequently reported comorbidities in children and adolescents with COVID-19 were: asthma (n=753, 0.8%), neuromuscular diseases (n=49) and diabetes (n=55). Most patients with asthma or neurological disease were males, whereas most patients with diabetes were females (table 3).

**Hospital and PICU admissions and deaths**

A total of 476 children were admitted to hospital with a COVID-19 International Classification of Diseases 10th Revision code, either as primary or secondary diagnosis. Children aged from 0 to 4 years represented 47.9% (228) of hospital admissions, corresponding to 2.24% of all COVID-19 cases in this age group during this time. Overall, 2.8 per 10,000 children in Portugal required hospital admission (table 4). No other sociodemographic or clinical variables were available to further characterise this population.

A total of 32 children required PICU admission, corresponding to 0.19 PICU admissions per 10,000 children.
and adolescents in Portugal. Of these, 28 (87.5%) were admitted due to MIS-C and 4 (12.5%) due to severe COVID-19. MIS-C patients were predominantly male (21, 75%) with ages from 15 months to 17 years of age, average of 10.75 and median of 10.5 years. Most cases occurred between January and February 2021. Six patients presented comorbidities. Patients with severe COVID-19 were mainly females, under the age of 1 and all presenting with comorbidities. Two deaths caused by COVID-19 were reported by the DGS (the National Health Authority) during this study and coincided with two deaths recorded in the SINAOVE database.

DISCUSSION

In this study, epidemiological and clinical characteristics of paediatric COVID-19 infections, hospital and PICU admissions in Portugal were described. Health surveillance information analysis revealed an essential and urgent need for improvement.

General characteristics: although there is accessible and exhaustive knowledge regarding adult COVID-19, paediatric COVID-19 epidemiology and clinical characteristics are significantly less studied and documented in the literature. SARS-CoV-2 infection studies have shown that children are more likely to be asymptomatic than adults and present a less severe disease course. Young children and infants are reported as more vulnerable to infection than older paediatric patients. COVID-19-related fatalities have been reported as scarce in the paediatric population. In this context, we assessed the characteristics and clinical features of COVID-19 in children in Portugal.

We observed an increase of COVID-19 cases with age in both sexes with slightly higher number of cases in males compared with females (50.5% vs 49.5%). Overall, in the scientific literature, males are most affected, although individual smaller studies have shown either sex as being the most frequent.

Most of these cases were geographically clustered in the high-density urban areas of Lisbon, Porto and Braga. The association between population density and cumulative infection cases spread was previously observed at a county level in the USA and considered an effective predictor of cumulative infection cases. The regions with lower number of cases were mainly rural and low-density populated districts, such as Portalegre, Beja and the autonomous regions of the Azores and Madeira. The nationality of paediatric patients with COVID-19 reflects the population’s background. The majority were Portuguese and 4% come from diverse backgrounds such as Brazil, Angola, Cape Verde and São Tome and Principe, countries with historical ties and emigration patterns to Portugal.

Several COVID-19 waves were observed in our study. Following the first wave, in March and April 2020, the first State of Emergency and lockdown were
implemented, including school closures, mandatory remote work, limiting mobility, business hours and social gatherings. Between 17 March and 2 April, all children who attended the emergency department (ED) of a Portuguese hospital with suspected COVID-19 symptoms as cough, fever or rhinorrhoea were tested. Of all 94 cases, 1 was positive. This can indicate a low incidence of disease at this stage, which is in accordance with our results. Studies on antibody seroprevalence of SARS-CoV-2 have shown that only half the children and adolescents had developed disease symptoms.

Clinical presentation and comorbidities: the most common symptoms identified (cough, fever, rhinorrhoea and headache) have been dominant in meta-analysis describing clinical characteristics of children. Wang et al reported the presence of fever in 48% and cough in 39% of the cases. This can indicate a low incidence of disease at this stage, which is in accordance with our results. Studies on antibody seroprevalence of SARS-CoV-2 have shown that only half the children and adolescents had developed disease symptoms.

Asthma was the most common underlying condition and has been the most reported comorbidity among several paediatric cases as well. Verma et al analysed SARS-CoV-2 infections in children in four hospitals in the New York City area and found those with asthma were more likely to need respiratory support during hospitalisation. In a systematic review, including 5686 children aged under 18 years with SARS-CoV-2 infection, the most frequent comorbidity was cardiac disease; and most children who required ventilation had underlying comorbidities. A study of ED and admitted paediatric patients with COVID-19 at a Level 3 Lisbon Hospital, one of two reference hospitals for paediatric patients with COVID-19 at this point in the pandemic, showed 10% had risk factors for disease, 20% were asymptomatic, 43% presented with symptoms per age groups can be organised in three sets: (1) from ages 0 to 4 years: fever, cough and rhinorrhoea; (2) from ages 5 to 9 years: fever, cough, rhinorrhoea and headache and (3) from 10 to 17 years: the previous four symptoms, odynophagia and myalgia. This result can reflect simultaneously the inability of young children to express their complaints and an increase in the variety of symptoms and presentations as age increases.

### Table 3 Comorbidities of the paediatric COVID-19 cases, from March 2020 to February 2021, in Portugal

| Comorbidities                                      | Total N (%) | Female N (%) | Male N (%) |
|---------------------------------------------------|-------------|--------------|------------|
| Total cases with comorbidities‡                   | 1593        | 691          | 902        |
| Total cases with known comorbidities              | 1000        | 427          | 573        |
| Number of comorbidities                           |             |              |            |
| 0                                                 | 18 087 (94.9%) | 9013 (95.5%) | 9074 (94.1%) |
| 1                                                 | 943 (4.9%)    | 401 (4.2%)   | 542 (6.0%)  |
| 2                                                 | 47 (0.2%)     | 20 (0.2%)    | 27 (0.3%)   |
| 3+                                                | 10 (0.1%)     | 6 (0.1%)     | 4 (0.0%)    |
| Total                                             | 19 087       | 9440         | 9647        |

Results of each morbidity were presented considering the sample size of cases with any reported morbidity (n=1593). Global percentage. Percentage within sex level. Total cases with comorbidities, of which 1000 are specified.
fever and 42% with respiratory symptoms. Although the referred study is likely representing the most symptomatic COVID-19 cases seeking medical help, our study focuses on all paediatric COVID-19 cases, chronic respiratory disease was also the most common comorbidity. Only a small proportion of children with COVID-19 had registered comorbidities (n=1593, 2%), which is lower than reported in other studies and of what the authors expected.

Given the abnormally high number of missing clinical presentations (48%, n=44 177) and comorbidities (98%, n=72 371), the quality of surveillance data was assessed. Statistical significant data results progressively worsened with the pandemic and particularly when case numbers sharply increased. These results can be consequential of massive work overload observed in the public health units combined with short staff. Furthermore, with increasing case counts, non-public healthcare professionals were recruited to support the units. However, significant asymmetries were also evident according to district, with substantial fluctuations in recording rates across the country. The two districts with the highest recorded data were Lisbon and Faro, whereas the lowest recorded on disease presentation were Guarda and Bragança and on the presence of comorbidities were Évora, Bragança, Guarda and Portalegre. Notwithstanding, good practice and the SINAVE guidelines warrant all fields to be answered and to achieve this goal measures and geographically adapted strategies, such as increased training, resources and continued auditing, need to be implemented to improve data surveillance. The SINAVE system collects symptoms and comorbidities in a non-mandatory and non-intelligent way, not tailored to previous answers. This system also needs to be improved from a user perspective so to fast-track user experience and enhance clinical record keeping. An opportunity for improvement in the Portuguese surveillance data collection system needs to be recognised, so it can be improved with increased training, geographic adapted strategies and information systems to facilitate adequate epidemiological surveillance collection. These data are essential to guide public health strategies, policy decision making, audit and research.

Hospital and PICU admissions: in 2020, a total of 476 children were admitted to the hospital from 51 153 cases reported, corresponding to 1 in 108 cases requiring hospitalisation, a rate of 0.93% of cases nationwide and a paediatric hospitalisation rate of 2.8 per 10 000 children and adolescents. A lower case hospitalisation result than reported in neighbouring Navarra, Spain (3.6%) during the first wave, in the USA (5.3%) and in Scotland, where 1.03% of cases in children aged 5–17 years required hospitalisation. These results might reflect a higher testing rate of asymptomatic or mildly ill children in Portugal.

| Table 4 | Paediatric hospital from March 2020 to December 2020 and PICU admissions from March 2020 to February 2021 in Portugal |
|---------|------------------------------------------------------------------------------------------------------------------|
| Hospital admissions from March to December 2020 |
| Age group | Hospital admissions n (%) | Cases per age group | Hospital admissions per 100 reported cases | Hospital admissions per 10 000 children |
| 0–4 | 228 (47.9%) | 10 161 | 2.24 | 5.2 |
| 5–11 | 112 (23.5%) | 18 358 | 0.61 | 1.7 |
| 12–17 | 136 (28.6%) | 22 674 | 0.60 | 2.2 |
| Total | 476 (100%) | 51 193 | 0.93 | 2.8 |
| PICU admissions from March 2020 to February 2021 |
| PICU admissions (%) | Severe COVID-19 | MIS-C | Total ICU admissions |
| PICU admissions per 10 000 reported cases | 4 (12.5%) | 28 (87.5%) | 32 (100%) |
| PICU admissions per 10 000 children | 0.02 | 0.16 | 0.19 |
| Female (%) | 3 (75%) | 7 (25%) | 10 (31.2%) |
| Male (%) | 1 (25%) | 21 (75%) | 22 (68.8%) |
| Minimum age (months) | 3 | 15 |
| Maximum age (years) | 17 | 17 |
| Median (years) | 0 | 10.5 |
| Comorbidities present (%) | 4 (100%) | 6 (21.4%) | 10 (31.2%) |

MIS-C, multisystem inflammatory disease in children; PICU, paediatric intensive care unit.
Thirty-two cases required PICU admission, corresponding to a rate of admission of 3.48 per 10 000 cases. Four cases (12.5%) were admitted with severe COVID-19 (non-MIS-C) and 28 (87.5%) with MIS-C, implying that in our population, severe COVID-19 in children is less frequent than MIS-C. Patients with severe COVID-19 were predominantly female under 1 with comorbidities, whereas MIS-C patients were predominantly male and the majority (75%) had no comorbidities, which is similar to previously published results, where most MIS-C patients were healthy, and no correlation was observed between comorbidity score and MIS-C occurrence.29

Deaths: during this period, the DGS confirmed two paediatric deaths caused by COVID-19, corresponding to a case fatality rate of approximately 1.8 per 100 000 cases. Furthermore, analysing specifically total paediatric deaths in Portugal in 2020 (n=387) and comparing with the paediatric COVID-19 deaths, COVID-19 was the main cause of death in 0.52%. The mortality rate due to COVID-19 was 1.2 per million children and adolescents. These results find parallel to similar studies, highlighting the low mortality and case fatality rates. Despite the extremely small number of deaths, it is reasonable to compare these results with other countries. Bhopal et al reported an overall mortality rate due to COVID-19 in children of 1.7 per 10 000, until February 2021 when comparing seven countries. Smith et al reported a mortality rate due to COVID-19 of 2 per million and fatality rate of 5 per 100 000 in England, between March 2020 and February 2021, a result 1.7 and 2.5 times higher than the one we reported, respectively. Spanish mortality results were published by Tagarro et al and reported 0.21 per 100 000 in children aged 0–9 years and 0.34 per 100 000 in children aged 10–19 years. These results may reflect differences in shielding of vulnerable population or lockdown policies implemented in these countries, but further studies are required to analyse these effects.

The major strengths of our study are the combined analysis of a large database of COVID-19 cases, hospital and PICU admissions and deaths. These results present a description of paediatric COVID-19 in Portugal and allow comparison with other countries.

The authors found the high level of missingness in surveillance data unusual. The analysis of real-world data has important challenges as previously acknowledged,30 however other studies using national data have reported similar difficulties.31 32 Despite the authors’ best effort in this analysis, less than optimal real-world data have imposed important limitations to the study and hindered some of its quality, particularly relating to missing values in some of the analysed variables. The authors are developing further studies and proposing solutions to help prevent these issues.31 32 As stated, the major limitations of this analysis are data-related, the possible under-reporting of cases and its characteristics, such as symptoms and comorbidities, the limited access to hospital admission data and deaths and the impracticality of establishing a chronological order of events. Furthermore, the pediatric mid 2020 population was used by proxy as an estimate population for the period analyzed.

CONCLUSIONS

The overall reported case incidence was 5.4 per 100 children and adolescents and <1% of cases required hospital admission. MIS-C was more frequent in patients with no comorbidities and males, severe COVID-19 was rarer and occurred mainly in children under 1 year of age and females, all with comorbidities. Case fatality rates and mortality rates were low when comparing with other countries. This study highlights the need to improve epidemiological surveillance data in Portugal, with geographic adapted strategies, and information systems to facilitate adequate epidemiological surveillance data quality (online supplemental file 1).

Acknowledgements The authors would like to thank Dr Cristina Camilo and the EPICENTRE.PT research group.

Contributors CE planned the study and was the guarantor. She developed the methodology and was involved in obtaining the data, data analysis, writing the manuscript, creating tables/figures and reviewing the text. RF-S was involved in obtaining data, writing the manuscript, creating tables and figures and reviewing the text. CC was involved in planning the study, creating tables and figures, writing and reviewing the manuscript and maintaining references. MDAN was involved in writing and reviewing the manuscript. AC was involved in writing and reviewing the manuscript. CF was involved in writing and reviewing the manuscript. PN was involved in planning the study, data analysis and writing and reviewing the manuscript.

Funding Funds from Fundação para a Ciência e a Tecnologia to the Instituto de Saúde Ambiental, Faculdade de Medicina, Universidade de Lisboa (UIDB/04295/2020).

Map disclaimer The inclusion of any map (including the depiction of any boundaries therein), or of any geographic or locational reference, does not imply the expression of any opinion whatsoever on the part of BMJ concerning the legal status of any country, territory, jurisdiction or area or of its authorities. Any such...
expression remains solely that of the relevant source and is not endorsed by BMJ. Maps are provided without any warranty of any kind, either express or implied.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants but was not approved by Epidemiological study involving anonymous database.

Provenance and peer review Not commissioned; externally peer reviewed.

Data accessibility statement Data may be obtained from a third party and are not publicly available.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs Cecilia Elias http://orcid.org/0000-0002-3922-7152

Rodrigo Feteira-Santos http://orcid.org/0000-0002-5780-2288

Miguel de Araújo Nobre http://orcid.org/0000-0002-7084-8301

Andrea Silva Costa http://orcid.org/0000-0002-2727-4402

Leonar Baceral-Nicolaou http://orcid.org/0000-0003-0421-1262

Cristina Furtado http://orcid.org/0000-0003-6232-0945

Paulo Jorge Nogueira http://orcid.org/0000-0001-8316-5035

REFERENCES

1 Cucinotta D, Vanelli M, WHO Declares COVID-19 a pandemic. Acta Biomed 2020;91:157–60.

2 WHO/Europe. Coronavirus disease (COVID-19) outbreak - WHO announces COVID-19 outbreak a pandemic; 2019.

3 Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239–42.

4 Williams N, Radia T, Harman K, et al. COVID-19 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidity. Eur J Pediatr 2021;180:689–97.

5 Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:759–65.

6 Bialek S, Gierke R, Hughes M, et al. COVID-19 Outbreak Among Children: United States, February 12–April 2, 2020. MMWR Morb Mortal Wkly Rep 2020;69:423–6.

7 Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020;145. doi:10.1542/peds.2020-0702. [Epub ahead of print: 16 03 2020].

8 Mantova N, Rinaldi E, Zusi C, et al. Coronavirus disease 2019 (COVID-19) in children and/or adolescents: a meta-analysis. Pediatr Res 2021;89:733–7.

9 Götzinger F, Santiago-García B, Nogueira-Julian A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health 2020;4:653–61.

10 Zare-Zandip H, Solanteena H, Farsalios F, et al. Coronavirus disease 2019 (COVID-19) in children: prevalence, diagnosis, clinical symptoms, and treatment. Int J Gen Med 2020;13:477–82.

11 Guo C-X, He L, Yin J-Y, et al. Epidemiological and clinical features of pediatric COVID-19. BMC Med 2020;18:1.7.

12 Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J 2020;39:355–68.

13 Davies NG, Klepac P, Liu Y, et al. Age-Dependent effects in the transmission and control of COVID-19 epidemics. Nat Med 2020;26:1205–11.

14 Wang Z, Zhou Q, Wang C, et al. Clinical characteristics of children with COVID-19: a rapid review and meta-analysis. Ann Transl Med 2020;8:620.

15 Mayor S. Covid-19: UK studies find gastrointestinal symptoms are common in children. BMJ 2020;370:m3484.

16 Giacometi V, Barcellini L, Stracuzzi M, et al. Gastrointestinal symptoms in severe COVID-19 children. Pediatr Infect Dis J 2020;39:E317–20.

17 Borrelli M, Coccione A, Castellano F, et al. Coronavirus disease 2019 in children. Front Pediatr 2020;9.

18 Patel NA. Pediatric COVID-19: systematic review of the literature. Am J Otolaryngol 2020;41:102573.

19 Ward JL, Harwood R, Smith C, et al. Risk factors for PICU admission and death among children and young people hospitalized with COVID-19 and PIMS-TS in England during the first pandemic year. Nat Med 2022;28:193–200.

20 Maltezou HC, Vorou R, Papadima K, et al. Transmission dynamics of SARS-CoV-2 within families with children in Greece: a study of 23 clusters. J Med Virol 2021;93:1414–20.

21 Han Y-N, Feng Z-W, Sun L-N, et al. A comparative-descriptive analysis of clinical characteristics in 2019-coronavirus-infected children and adults. J Med Virol 2020:92:1596–602.

22 Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis 2020;20:911–9.

23 Kawasui T, Takegoshi Y, Kaneda M, et al. Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients. PLoS One 2020;15:e0243597.

24 Ibrahim NKR, Al Bar HM. Surveillance of childhood vaccine-preventable diseases at health facilities in Jeddah, Saudi Arabia. East Mediterr Health J 2009;15:532–43.

25 Choi BCK. The Past, Present, and Future of Public Health Surveillance. In: Eriksson K, Mastrangelo G, eds. Scientifica, 2012;1, 26–.

26 European Centre for Disease Prevention and Control. Data quality, monitoring and surveillance system evaluation – A Handbook of methods and applications. Stockholm: ECDC, 2014.

27 World Health Organization. Laboratory testing of 2019 novel coronavirus (2019-nCoV) in suspected human cases: interim guidance, 17 January 2020; 2020: 1–7.

28 Direção Geral da Saúde (DGS). Comissão Técnica de Vacinação Contra a COVID-19 Vacinação Contra a COVID-19 em crianças CoM 5 a 11 anos; 2020.

29 Preston LE, Chevin DA, Kompaniyets L, et al. Characteristics and disease severity of US children and adolescents diagnosed with COVID-19. JAMA Netw Open 2021;4:e215298.

30 World Health Organization (WHO). Living guidance for clinical management of COVID-19: living guidance, 23 November 2021.

31 Lechien JR, Chiesa-Davies NG, Klepac P, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med 2020;288:335–44.

32 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.

33 Adeyinka A, Bailey K, Pierre L, et al. COVID-19 infection: pediatric perspectives. J Am Coll Emerg Physicians Open 2021;2:1–11.

34 Wong DWS, Li Y, Spooning of COVID-19: density matters. PLoS One 2020;15:e0242398.

35 Diário da República. Diário da República 1.a série. Decreto do Presidente da República n.o 14-A/2020 de 18 de Março; 2020.

36 Costa A, Almeida H, Moniz M, COVID-19 screening in a Portuguese pediatric population. Enferm Infeccious y Microbiología Clinica 2020;38:9–12.

37 Felsenstein S, Hiedrich CM, SARS-CoV-2 infections in children and young people. Clin Immunol 2020;220:108588.

38 Wang Z, Zhou Q, Wang C, et al. Clinical characteristics of children with COVID-19: a rapid review and meta-analysis. Ann Transl Med 2020;8:620.

39 Li B, Zhang S, Zhang R, et al. Epidemiological and clinical characteristics of COVID-19 in children: a systematic review and meta-analysis. Front Pediatr 2020;8:591132.

40 Watkissfield T, Watson MB, Sunobre F, et al. Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study. Arch Dis Child 2021;106:680–6.
SUPPLEMENTARY TABLE 1. PEDIATRIC COVID-19 CASES COUNTRY OF ORIGIN, EXCLUDING PORTUGAL

| Country                    | n(%)       |
|----------------------------|------------|
| Brasil                     | 2170 (59.2%)|
| Angola                     | 331 (9.0%) |
| Cape Verde                 | 205 (5.6%) |
| Saint Tome and Principe    | 121 (3.3%) |
| Guine Bissau               | 86 (2.3%)  |
| Nepal                      | 75 (2.0%)  |
| Ukraine                    | 72 (2.0%)  |
| Italy                      | 66 (1.8%)  |
| France                     | 62 (1.7%)  |
| Venezuela                  | 49 (1.3%)  |
| Spain                      | 47 (1.3%)  |
| United Kingdom             | 45 (1.2%)  |
| Romenia                    | 45 (1.2%)  |
| India                      | 33 (0.9%)  |
| Bangladesh                 | 27 (0.7%)  |
| Mozambique                 | 23 (0.6%)  |
| Netherlands                | 19 (0.5%)  |
| Republic of Moldava        | 17 (0.5%)  |
| Germany                    | 16 (0.4%)  |
| Paquistan                  | 16 (0.4%)  |
| Belgium                    | 14 (0.4%)  |
| Bulgaria                   | 14 (0.4%)  |
| Colombia                   | 12 (0.3%)  |
| Cuba                       | 9 (0.2%)   |
| Ireland                    | 9 (0.2%)   |
| China                      | 7 (0.2%)   |
| United States of America   | 7 (0.2%)   |
| Other                      | 67 (1.8%)  |
SUPPLEMENTARY TABLE 2. SYMPTOMATIC AND ASYMPTOMATIC COVID-19 CASES PER AGE

| Years | Asymptomatic n (%) | Symptomatic n (%) | Total | Total reported cases | Missing information n (%) |
|-------|-------------------|------------------|-------|----------------------|--------------------------|
| 0     | 162 (15.1%)       | 913 (84.9%)      | 1075  | 1719                 | 644 (37.5%)              |
| 1     | 387 (15.9%)       | 2040 (84.1%)     | 2427  | 3725                 | 1298 (34.8%)             |
| 2     | 485 (22.6%)       | 1658 (77.4%)     | 2143  | 3692                 | 1549 (42%)               |
| 3     | 527 (28.2%)       | 1342 (71.8%)     | 1869  | 3332                 | 1463 (43.9%)             |
| 4     | 640 (34.1%)       | 1237 (65.9%)     | 1877  | 3709                 | 1832 (49.4%)             |
| 5     | 704 (34.7%)       | 1325 (65.3%)     | 2029  | 4023                 | 1994 (49.6%)             |
| 6     | 769 (36%)         | 1367 (64%)       | 2136  | 4299                 | 2163 (50.3%)             |
| 7     | 825 (36.4%)       | 1442 (63.6%)     | 2267  | 4592                 | 2325 (50.6%)             |
| 8     | 871 (34.7%)       | 1640 (65.3%)     | 2511  | 5058                 | 2547 (50.4%)             |
| 9     | 966 (34.6%)       | 1824 (65.4%)     | 2790  | 5548                 | 2758 (49.7%)             |
| 10    | 918 (33%)         | 1868 (67%)       | 2786  | 5705                 | 2919 (51.2%)             |
| 11    | 892 (31.6%)       | 1930 (68.4%)     | 2822  | 5726                 | 2904 (50.7%)             |
| 12    | 879 (30.2%)       | 2029 (69.8%)     | 2908  | 5865                 | 2957 (50.4%)             |
| 13    | 816 (26.8%)       | 2229 (73.2%)     | 3045  | 6080                 | 3035 (49.9%)             |
| 14    | 869 (27.2%)       | 2329 (72.8%)     | 3198  | 6449                 | 3251 (50.4%)             |
| 15    | 829 (23.5%)       | 2702 (76.5%)     | 3531  | 6919                 | 3388 (49%)               |
| 16    | 778 (19.9%)       | 3139 (80.1%)     | 3917  | 7635                 | 3718 (48.7%)             |
| 17    | 760 (18.4%)       | 3379 (81.6%)     | 4139  | 7975                 | 3836 (48.1%)             |

Total 13077 (27.5%) 34393 (72.4) 47470 92051 44581 (48.4%

Footnote: Asymptomatic and symptomatic percentages calculated from all patients with known disease presentation; Missing information percentages calculated from all patients within an age bracket.
### SUPPLEMENTARY TABLE 3. DISTRIBUTION OF SYMPTOMS OF PAEDIATRIC COVID-19 CASES

| Symptoms** | Fever | Cough | Rhinorrhea | Dyspnea | Headache | Diarrhoea | Abdominal pain | Odynophagia | Nausea and Vomiting | Arthralgia | Myalgia | Tiredness and weakness | Tachycardia | Chest pain | Irritability | Convulsions |
|------------|-------|-------|------------|---------|----------|-----------|---------------|-------------|-------------------|-----------|---------|---------------------|------------|------------|-------------|------------|
| Fever      | 3721 (37.2%) | 3203 (32%) | 2902 (29.8%) | 314 (3.2%) | 2824 (28.6%) | 1060 (10.2%) | 1060 (10.2%) | 845 (8.7%) | 430 (4.3%) | 342 (3.4%) | 48 (6%) | 351 (3.5%) | 319 (3.1%) | 24 (1.5%) | 16 (1.5%) | 6 (0.6%) |
| Cough      | 3721 (37.2%) | 4203 (42%) | 366 (4.8%) | 366 (4.8%) | 3724 (37.8%) | 2902 (29.1%) | 2902 (29.1%) | 430 (4.3%) | 342 (3.4%) | 48 (6%) | 351 (3.5%) | 319 (3.1%) | 24 (1.5%) | 16 (1.5%) | 6 (0.6%) |
| Rhinorrhea | 2902 (29.8%) | 4203 (42%) | 2902 (29.1%) | 314 (3.2%) | 2824 (28.6%) | 1060 (10.2%) | 1060 (10.2%) | 845 (8.7%) | 430 (4.3%) | 342 (3.4%) | 48 (6%) | 351 (3.5%) | 319 (3.1%) | 24 (1.5%) | 16 (1.5%) | 6 (0.6%) |
| Dyspnea    | 314 (3.2%) | 584 (5.8%) | 366 (4.8%) | 366 (4.8%) | 2824 (28.6%) | 1060 (10.2%) | 1060 (10.2%) | 845 (8.7%) | 430 (4.3%) | 342 (3.4%) | 48 (6%) | 351 (3.5%) | 319 (3.1%) | 24 (1.5%) | 16 (1.5%) | 6 (0.6%) |
| Headache   | 2824 (29%) | 2724 (27.2%) | 1976 (20.2%) | 228 (2.3%) | 2046 (20.8%) | 1060 (10.2%) | 1060 (10.2%) | 845 (8.7%) | 430 (4.3%) | 342 (3.4%) | 48 (6%) | 351 (3.5%) | 319 (3.1%) | 24 (1.5%) | 16 (1.5%) | 6 (0.6%) |
| Diarrhoea  | 1060 (10.9%) | 790 (7.9%) | 568 (7.4%) | 568 (7.4%) | 2902 (29.1%) | 1060 (10.2%) | 1060 (10.2%) | 845 (8.7%) | 430 (4.3%) | 342 (3.4%) | 48 (6%) | 351 (3.5%) | 319 (3.1%) | 24 (1.5%) | 16 (1.5%) | 6 (0.6%) |
| Abdominal pain | 845 (8.7%) | 430 (4.3%) | 342 (3.4%) | 342 (3.4%) | 2824 (28.6%) | 1060 (10.2%) | 1060 (10.2%) | 845 (8.7%) | 430 (4.3%) | 342 (3.4%) | 48 (6%) | 351 (3.5%) | 319 (3.1%) | 24 (1.5%) | 16 (1.5%) | 6 (0.6%) |
| Odynophagia | 2046 (21%) | 2310 (23.1%) | 1746 (17.7%) | 132 (1.3%) | 2055 (20.8%) | 1060 (10.2%) | 1060 (10.2%) | 845 (8.7%) | 430 (4.3%) | 342 (3.4%) | 48 (6%) | 351 (3.5%) | 319 (3.1%) | 24 (1.5%) | 16 (1.5%) | 6 (0.6%) |
| Nausea and Vomiting | 992 (10.2%) | 562 (5.6%) | 415 (5.4%) | 415 (5.4%) | 2824 (28.6%) | 1060 (10.2%) | 1060 (10.2%) | 845 (8.7%) | 430 (4.3%) | 342 (3.4%) | 48 (6%) | 351 (3.5%) | 319 (3.1%) | 24 (1.5%) | 16 (1.5%) | 6 (0.6%) |
| Arthralgia  | 81 (0.8%) | 74 (0.7%) | 68 (0.7%) | 68 (0.7%) | 430 (4.3%) | 342 (3.4%) | 342 (3.4%) | 430 (4.3%) | 342 (3.4%) | 48 (6%) | 351 (3.5%) | 319 (3.1%) | 24 (1.5%) | 16 (1.5%) | 6 (0.6%) |
| Myalgia    | 513 (5.1%) | 436 (4.3%) | 342 (3.4%) | 342 (3.4%) | 2824 (28.6%) | 1060 (10.2%) | 1060 (10.2%) | 845 (8.7%) | 430 (4.3%) | 342 (3.4%) | 48 (6%) | 351 (3.5%) | 319 (3.1%) | 24 (1.5%) | 16 (1.5%) | 6 (0.6%) |
| Tiredness and weakness | 752 (7.7%) | 752 (7.5%) | 565 (7.4%) | 565 (7.4%) | 2824 (28.6%) | 1060 (10.2%) | 1060 (10.2%) | 845 (8.7%) | 430 (4.3%) | 342 (3.4%) | 48 (6%) | 351 (3.5%) | 319 (3.1%) | 24 (1.5%) | 16 (1.5%) | 6 (0.6%) |
| Tachycardia | 52 (0.5%) | 30 (0.3%) | 22 (0.3%) | 22 (0.3%) | 2824 (28.6%) | 1060 (10.2%) | 1060 (10.2%) | 845 (8.7%) | 430 (4.3%) | 342 (3.4%) | 48 (6%) | 351 (3.5%) | 319 (3.1%) | 24 (1.5%) | 16 (1.5%) | 6 (0.6%) |
| Chest pain | 156 (1.6%) | 261 (2.6%) | 144 (1.4%) | 102 (1.1%) | 2055 (20.8%) | 1060 (10.2%) | 1060 (10.2%) | 845 (8.7%) | 430 (4.3%) | 342 (3.4%) | 48 (6%) | 351 (3.5%) | 319 (3.1%) | 24 (1.5%) | 16 (1.5%) | 6 (0.6%) |
| Irritability | 56 (0.6%) | 40 (0.4%) | 33 (0.4%) | 33 (0.4%) | 2824 (28.6%) | 1060 (10.2%) | 1060 (10.2%) | 845 (8.7%) | 430 (4.3%) | 342 (3.4%) | 48 (6%) | 351 (3.5%) | 319 (3.1%) | 24 (1.5%) | 16 (1.5%) | 6 (0.6%) |
| Convulsions | 25 (0.3%) | 18 (0.2%) | 11 (0.1%) | 11 (0.1%) | 2824 (28.6%) | 1060 (10.2%) | 1060 (10.2%) | 845 (8.7%) | 430 (4.3%) | 342 (3.4%) | 48 (6%) | 351 (3.5%) | 319 (3.1%) | 24 (1.5%) | 16 (1.5%) | 6 (0.6%) |

**Footnote:** *Percentages calculated from symptomatic patients with specified symptoms.** **Percentages calculated from patients with column symptom.*
